Cholesterol Lowering Via Bempedoic Acid/Ezetimibe, an ACL-Inhibiting Regimen in Acute Coronary Syndrome Study
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 500 participants.
Also called NCT05263778
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 500 participants
- Registry
-
NCT05263778
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Unknown status
Technical summary
Registry record NCT05263778. Randomized; quadruple masking; primary purpose prevention. Start 2022-03 (anticipated); primary completion 2023-06 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Cholesterol Lowering Via Bempedoic Acid/Ezetimibe, an ACL-Inhibiting Regimen in Acute Coronary Syndrome Study
- Condition
- Cardiovascular Diseases
- Condition
- NSTEMI
- Condition
- STEMI
- Intervention (Drug)
- Bempedoic Acid / Ezetimibe Oral Tablet
- Intervention (Drug)
- Placebo
- Lead sponsor
- Kaiser Permanente
- Collaborator
- Esperion Therapeutics, Inc.
Record details
- Record id
cardio:ct-nct05263778- Content hash
d79aa37f51cc6103b237bb9c4dabd81a9eea11ee536de58a53072441266a4d41